Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma
10.3760/cma.j.cn112138-20250613-00344
- VernacularTitle:西达本胺联合BEAM预处理方案自体造血干细胞移植治疗淋巴瘤的疗效及安全性分析
- Author:
Yuanli GONG
1
;
Siying PAN
1
;
Tongyao XING
1
;
Hua YIN
1
;
Haorui SHEN
1
;
Li WANG
1
;
Jinhua LIANG
1
;
Jianyong LI
1
;
Wei XU
1
Author Information
1. 南京医科大学第一附属医院（江苏省人民医院）血液科，南京 210029
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Autologous hematopoietic stem cell transplantation;
High-risk, relapsed/refractory;
Chidamide
- From:
Chinese Journal of Internal Medicine
2025;64(12):1211-1217
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of the Chi-BEAM regimen (chidamide combined with carmustine, etoposide, cytarabine, and melphalan) followed by autologous hematopoietic stem cell transplantation (ASCT) in patients with high-risk or relapsed/refractory lymphoma.Methods:This retrospective case series included 78 patients with newly treated high-risk or relapsed/refractory lymphoma who underwent ASCT with the Chi-BEAM conditioning regimen in the Department of Hematology, the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), from June 2021 to May 2024. Descriptive statistics were employed to evaluate clinical characteristics, efficacy, and adverse events. The Kaplan-Meier method was applied to calculate cumulative progression-free survival (PFS) and overall survival (OS) rates.Results:The median age of the 78 evaluable patients was 47 years (range 16-68), with 8 patients (10.3%) aged ≥60 years. At the first post-transplant assessment (3 months), the objective response rate was 94.9% (74/78). The median follow-up was 20.1 months (range 2.9-44.9). The median PFS time was 20.1 months (range 1.6-45.1), with a 2-year cumulative PFS rate of 81.8%. The median OS time was 20.6 months (range 3.1-45.1), with a cumulative 2-year OS rate of 93.2%. The regimen was well-tolerated; mild-to-moderate hypocalcemia within 1 week post-infusion and transient mild erythrocyturia on the infusion day were the primary adverse reactions.Conclusion:The Chi-BEAM regimen combined with ASCT demonstrates both safety and clinical benefit in patients with high-risk or relapsed/refractory lymphoma.
